<i>EGFR</i> mutations and high PD-L1 expression of lung squamous cell carcinoma patients achieving pCR following neoadjuvant immuno-chemotherapy: Case report.

Xu, Xiangyu; Shi, Zixia; Fu, Dan; Huang, Depei; Ma, Zheng

EGFR mutations and high PD-L1 expression of lung squamous cell carcinoma patients achieving pCR following neoadjuvant immuno-chemotherapy: Case report.

Xu, Xiangyu; Shi, Zixia; Fu, Dan; Huang, Depei; Ma, Zheng.

Afiliación

Xu X; Department of Thoracic Surgery, Chongqing General Hospital, Chongqing, China.
Shi Z; Department of Thoracic Surgery, Chongqing General Hospital, Chongqing, China.
Fu D; The Medical Department, 3D Medicines Inc., Shanghai, China.
Huang D; The Medical Department, 3D Medicines Inc., Shanghai, China.
Ma Z; Department of Thoracic Surgery, Chongqing General Hospital, Chongqing, China.

Front Oncol ; 12: 1008932, 2022.

Article en En | MEDLINE | ID: mdl-36338754

Palabras clave

epidermal growth factor receptor (EGFR); lung squamous cell carcinoma; mutations; neoadjuvant immunotherapy; pembrolizumab; programmed death ligand-1 (PD-L1)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google